194 related articles for article (PubMed ID: 37361601)
1. Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study.
Ding J; Leng Z; Gu H; Jing X; Song Y
Front Oncol; 2023; 13():1153131. PubMed ID: 37361601
[TBL] [Abstract][Full Text] [Related]
2. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
3. Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients.
Chen Y; Jiang N; Liang X; Chen N; Chen Y; Zhang C; Shi J; Guo R
Oncol Lett; 2023 Aug; 26(2):323. PubMed ID: 37415629
[TBL] [Abstract][Full Text] [Related]
4. Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports.
Lai L; Meng W; Wei J; Zhang X; Tan Z; Lu Y; Hou E
Medicine (Baltimore); 2021 Mar; 100(10):e25046. PubMed ID: 33725888
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study.
Wan C; Zhang Y; Liu P; Mei X; Cheng G; Pang J; Chen S; Xu J; Malhotra J; Qian H; Du Y
J Thorac Dis; 2023 Oct; 15(10):5648-5657. PubMed ID: 37969256
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
[TBL] [Abstract][Full Text] [Related]
7. Expression of
Zhang SL; Zhang CY; Chen YQ; Li YF; Xie Z; Zhang XC; Zhou Q; Zhong WZ; Huang J; Sun H; Zheng MY; Xiao FM; Yan HH; Lu DX; Lv ZY; Wu YL; Chen HJ; Yang JJ
J Thorac Dis; 2023 Sep; 15(9):4620-4635. PubMed ID: 37868836
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
9. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
[TBL] [Abstract][Full Text] [Related]
10. Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer.
Zhong RB; Xu JL; Lou YQ; Chu TQ; Zhong H; Han BH
Ann Palliat Med; 2020 Jul; 9(4):1681-1687. PubMed ID: 32575999
[TBL] [Abstract][Full Text] [Related]
11. Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.
Lu Y; Li Z; Zhu H; Zhao J; Xu M; Gu W
Ann Palliat Med; 2021 Dec; 10(12):12886-12893. PubMed ID: 35016432
[TBL] [Abstract][Full Text] [Related]
12. Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy.
Yu L; Hu Y; Xu J; Qiao R; Zhong H; Han B; Xia J; Zhong R
Int J Cancer; 2023 Aug; 153(3):635-643. PubMed ID: 37078587
[TBL] [Abstract][Full Text] [Related]
13. Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.
Mc Leer A; Foll M; Brevet M; Antoine M; Novello S; Mondet J; Cadranel J; Girard N; Giaj Levra M; Demontrond P; Audigier-Valette C; Letouzé E; Lantuéjoul S; Fernandez-Cuesta L; Moro-Sibilot D
Lung Cancer; 2022 May; 167():98-106. PubMed ID: 35183375
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of anlotinib with third-generation epidermal growth factor receptor tyrosine kinase inhibitors in untreated
Li T; Chang K; Qiu X; Lai Z; Luo Y; Chen J; Lv W; Lin Z; Pei X; Wu X; Wang X
Transl Lung Cancer Res; 2023 Jun; 12(6):1256-1263. PubMed ID: 37425401
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
[TBL] [Abstract][Full Text] [Related]
16. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer
Li T; Qian Y; Zhang C; Uchino J; Provencio M; Wang Y; Shi X; Zhang Y; Zhang X
Transl Lung Cancer Res; 2021 Apr; 10(4):1873-1888. PubMed ID: 34012799
[TBL] [Abstract][Full Text] [Related]
18. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic and molecular characteristics of
Yu L; Bazhenova L; Gold K; Tran L; Hilburn V; Vu P; Patel SP
Transl Lung Cancer Res; 2022 Mar; 11(3):452-461. PubMed ID: 35399568
[TBL] [Abstract][Full Text] [Related]
20. Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors.
Zhou Y; Bai H; Xia J; Xu WY; Cheng L; Xiong L
Ann Transl Med; 2021 Jul; 9(14):1150. PubMed ID: 34430591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
